title: A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.
abstract: WHIM-syndrome is an inherited immunodeficiency disorder with abnormal susceptibility to human papillomavirus (HPV) infection and diseases. We determined safety and immunogenicity to a quadrivalent HPV vaccine in WHIM-syndrome by detection of HPV-specific antibodies and lymphoproliferation. In virus-like-particle (VLP)-ELISA, a WHIM patient showed antibody titers up to 400 for HPV-6/11/16/18, whereas immuno-competent controls developed titers of 6400-25,600. In pseudovirion assays, the patient's neutralization titers ranged from 20 to 400 to the four HPV vaccine types, while titers of 1600-25,600 were detected in healthy vaccinees. Specific proliferation of PBMC of the WHIM patient to the HPV vaccine was demonstrated. This first report on response to HPV vaccination in WHIM-immunodeficiency highlights that patients with WHIM-syndrome, and probably other immunodeficiencies, may benefit from HPV immunoprophylaxis.
authors.affiliation: Laboratory of Viral Oncology (LVO), Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University Vienna, Vienna, Austria.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Handisurya
authors.forename: Christina
authors.initials: C
authors.lastname: Schellenbacher
authors.forename: Bärbel
authors.initials: B
authors.lastname: Reininger
authors.forename: Frieder
authors.initials: F
authors.lastname: Koszik
authors.forename: Philipp
authors.initials: P
authors.lastname: Vyhnanek
authors.forename: Andreas
authors.initials: A
authors.lastname: Heitger
authors.forename: Reinhard
authors.initials: R
authors.lastname: Kirnbauer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Förster-Waldl
mesh_terms: D049109:Cell Proliferation; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D056724:Immunity, Humoral / Q000276:immunology*; D007153:Immunologic Deficiency Syndromes / Q000151:congenital / Q000235:genetics / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D009500:Neutralization Tests; D053918:Papillomavirus Vaccines / Q000276:immunology*; D014771:Virion / Q000276:immunology
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines
references.citation: MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48
references.pmid: 17136024
references.citation: J Natl Cancer Inst. 1994 Apr 6;86(7):494-9
references.pmid: 8133532
references.citation: J Allergy Clin Immunol. 2005 Nov;116(5):1101-5
references.pmid: 16275383
references.citation: J Gen Virol. 2009 Jan;90(Pt 1):136-43
references.pmid: 19088282
references.citation: J Clin Invest. 2006 May;116(5):1167-73
references.pmid: 16670757
references.citation: Blood. 2004 Jul 15;104(2):444-52
references.pmid: 15026312
references.citation: Blood. 2000 Jan 1;95(1):320-7
references.pmid: 10607719
references.citation: J Virol. 2002 Aug;76(15):7832-42
references.pmid: 12097595
references.citation: Vaccine. 2007 Jun 21;25(26):4931-9
references.pmid: 17499406
references.citation: Blood. 2005 Mar 15;105(6):2449-57
references.pmid: 15536153
references.citation: Vaccine. 2007 May 22;25(21):4324-33
references.pmid: 17445955
references.citation: J Virol. 2009 Oct;83(19):10085-95
references.pmid: 19640991
references.citation: Vaccine. 2008 Dec 9;26(52):6844-51
references.pmid: 18930097
references.citation: Curr Allergy Asthma Rep. 2005 Sep;5(5):350-5
references.pmid: 16091205
references.citation: Am J Med. 1990 Nov;89(5):663-72
references.pmid: 2239986
references.citation: Lancet. 2009 Jul 25;374(9686):301-14
references.pmid: 19586656
references.citation: J Dtsch Dermatol Ges. 2009 May;7(5):453-66; quiz 466, 467
references.pmid: 19302229
references.citation: J Clin Invest. 2008 Mar;118(3):1074-84
references.pmid: 18274673
references.citation: Virology. 2004 Apr 10;321(2):205-16
references.pmid: 15051381
references.citation: Nat Genet. 2003 May;34(1):70-4
references.pmid: 12692554
references.citation: Exp Hematol. 2005 Apr;33(4):460-8
references.pmid: 15781337
references.citation: JAMA. 2007 Feb 28;297(8):813-9
references.pmid: 17327523
references.citation: J Immunol. 2006 Aug 15;177(4):2662-2670
references.pmid: 16888028
references.citation: Acta Paediatr Scand. 1980 Jul;69(4):549-51
references.pmid: 6255734
references.citation: J Infect Dis. 2009 Jul 15;200(2):166-71
references.pmid: 19519255
references.citation: Cancer Prev Res (Phila). 2009 Oct;2(10):868-78
references.pmid: 19789295
references.citation: N Engl J Med. 1964 Apr 2;270:699-704
references.pmid: 14101065
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: J Virol. 1993 Dec;67(12):6929-36
references.pmid: 8230414
references.citation: Curr Opin Hematol. 2009 Jan;16(1):20-6
references.pmid: 19057201
references.citation: J Infect Dis. 2001 May 15;183(10):1485-93
references.pmid: 11319684
references.citation: Vaccine. 2008 Aug 19;26 Suppl 10:K53-61
references.pmid: 18847557
references.citation: N Engl J Med. 2009 Jul 16;361(3):271-8
references.pmid: 19605832
references.citation: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
references.pmid: 1334560
references.citation: J Gen Virol. 1994 Sep;75 ( Pt 9):2445-9
references.pmid: 8077946
references.citation: Br J Cancer. 2006 Dec 4;95(11):1459-66
references.pmid: 17117182
references.citation: J Infect Dis. 2003 Jul 15;188(2):327-38
references.pmid: 12854090
references.citation: J Virol. 2004 Jan;78(2):751-7
references.pmid: 14694107
references.citation: N Engl J Med. 1977 Aug 4;297(5):241-5
references.pmid: 195206
references.citation: Methods Mol Med. 2005;119:445-62
references.pmid: 16350417
references.citation: Am J Med Genet. 2000 Apr 24;91(5):368-76
references.pmid: 10767001
references.citation: J Virol. 1995 Jun;69(6):3959-63
references.pmid: 7745754